What is CueZen?
Founded in 2021, CueZen operates at the intersection of artificial intelligence and personalized health engagement. The company provides a sophisticated AI platform that enables Health OEMs to transform raw data into actionable, personalized health journeys. By facilitating tailored programs, outcomes, and behavioral nudges, CueZen helps organizations such as Titan, the NHS, and Microport drive higher levels of user enrollment, engagement, and long-term adherence.
Beyond corporate partnerships, CueZen has demonstrated its scalability through large-scale public health initiatives, such as its deployment in Singapore, where it supports over 3 million residents in disease prevention through personalized interventions. This dual-track approach—serving both enterprise clients and large-scale government entities—positions CueZen as a foundational infrastructure provider in the modern health-tech landscape.
How much funding has CueZen raised?
CueZen has raised a total of $5M across 1 funding round:
Seed
$5M
Seed (2025): $5M with participation from Pack Ventures, Fortson VC, and Point72 Ventures
Key Investors in CueZen
Pack Ventures
Pack Ventures is an investment firm rooted in the University of Washington ecosystem that provides early-stage capital and hands-on support for transformative companies in AI, life sciences, and deep-tech.
Fortson VC
Fortson partners with unconventional thinkers and founders to build enduring companies through deep, data-driven insights and a quantitative framework that uncovers signals often overlooked by traditional diligence.
Point72 Ventures
Point72 Ventures is a venture capital firm specializing in early-stage investments across financial technology and enterprise software, leveraging deep institutional knowledge to help portfolio companies refine products and identify strategic partners.
What's next for CueZen?
With the successful closure of this major strategic investment, CueZen is well-positioned to deepen its technological moat and expand its reach into new international markets. The company's strategic roadmap likely involves enhancing its predictive modeling capabilities and integrating more complex behavioral science frameworks into its AI engine. As the demand for personalized health solutions continues to surge, CueZen's ability to deliver measurable outcomes at scale will be a key differentiator.
The focus moving forward will be on strengthening its enterprise partnerships and refining its intervention delivery systems. By maintaining its commitment to data-driven health outcomes, CueZen is poised to become an indispensable partner for global health organizations seeking to modernize their engagement strategies and improve patient health metrics through precision technology.
